Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for joining us and welcome to the Innate Pharma Full Year 2025 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialled into today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the conference over to Stephanie Kornan, Vice President of Investor Relations, Communications and Commercial Strategy at Innate Pharma. Please, Stephanie, go ahead. Thank you. Good morning and good afternoon everyone and thank you for joining us for Innate Pharma's full year 2025 business update and financial results conference call. The press release and today's presentation are available on the investor relations section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. I will briefly cover today's agenda. Our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. We will then share updates on our three priority programs, L'Aquitamab, IPH4502, and Monalizumab, as well as IPH5201 in partnership with AstraZeneca. Speakers will be our CMO Sonia Quarantino, our COO Yanis Morel, and I. Frédéric Lombard, CFO, will comment our financial results. Jonathan will return with upcoming catalysts and closing remarks before we open the call for Q&A. With that, I'll now hand it over to Jonathan. Thank you, Stephanie. Good morning to those joining from the US and good afternoon to our European audience. Turning to slide five, Innate Pharma is a focused oncology company with a clear ambition to deliv...